- Home
- NTIP vs BOLT Comparison
NTIP vs BOLT Comparison
Compare NTIP & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTIP | BOLT |
|---|---|---|
| Founded | 1990 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.4M | 7.3M |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NTIP | BOLT |
|---|---|---|
| Price | $1.59 | $3.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | ★ 28.8K | 13.1K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | ★ 7.30% | N/A |
| EPS Growth | ★ 15.38 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $150,000.00 | ★ $7,695,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $133.33 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 50.00 | 0.07 |
| 52 Week Low | $1.24 | $3.75 |
| 52 Week High | $1.75 | $7.20 |
Technical Indicators
Market Signals| Indicator | NTIP | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 54.78 | 49.48 |
| Support Level | $1.39 | $3.87 |
| Resistance Level | $1.66 | $4.46 |
| Average True Range (ATR) | 0.05 | 0.20 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 60.00 | 49.04 |
Price Performance
Historical ComparisonAbout NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.